37 results about "Interleukin 17" patented technology

The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and / or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.

The invention provides application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis. The structural formula of the 1 beta-hydroxy alantolactone is as follows: the 1 beta-hydroxy alantolactone is used for carrying out animal pharmaceutical effect tests, and results show that the 1 beta-hydroxy alantolactone obviously suppresses attack severity and morbidity of CIA (collagen-induced arthritis). TNF-alpha (tumor necrosis factors alpha), IL-17 (interleukin 17) and IFN-gamma (interferon gamma) in supernate of splenocyte can be reduced, secretion of proinflammatory cytokine TNF-alpha, IFN-gamma and IL-17 is suppressed, and accordingly CIA diseases are prevented. Accordingly, the application can be used for preparing medicine for treating rheumatoid arthritis. Medicine composition in the invention is prepared by the 1 beta-hydroxy alantolactone used as active ingredients and conventional medicine carriers and can be prepared into tablets, dispersible tablets, lozenge, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, granular formulation, injection, powder injection or aerosol and the like. The application has great clinical application values.

The invention discloses 2,3,4-trihydroxybenzenesulfonamide derivatives as well as a preparation method and an application thereof. The specific structure is shown in formula (I). In the formula (I), most of 2,3,4-trihydroxybenzenesulfonamide derivatives show good IL-17 (interleukin-17)A resistance activity. The IL-17A is related with autoimmune diseases and also related with occurrence and development of cancer. On the basis, the 2,3,4-trihydroxybenzenesulfonamide derivatives can be used for preparing immunoregulation drugs.

Provided are uses of IL-17 in enhancing an immune-suppression function of mesenchymal stem cells. In particular, the present invention provides uses of an interleukin-17, a derivative of interleukin-17 or an agonist thereof for preparing a preparation or kit for enhancing an immune-suppression function of the mesenchymal stem cells; up-regulating the expression of imunosuppressive factors in the mesenchymal stem cells; enhancing the stability of mRNAs of the immunosuppressive factors; reducing the expression level of RNA-binding protein AUF1; inhibiting the proliferation of T cells; and treating hepatitis or liver damage.

The invention provides an antibody specifically bound to interleukin 17 (IL-17A) with high affinity or a functional fragment of the antibody, and further provides a nucleic acid molecule coding the antibody or the functional fragment thereof, an expression vector used for expressing the antibody or the functional fragment thereof and a host cell, and a production method for the antibody or the functional fragment thereof. The invention further provides a pharmaceutical composition comprising the antibody or the functional fragment thereof, and a method for treating immune dysfunctional diseases by using the antibody or the functional fragment thereof.

A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and / or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

The invention provides application of berberine in preparing a medicament for preventing and treating rheumatoid arthritis. When the berberine is adopted for animal effectiveness test, results show that the berberine can inhibit clinical morbidity of collagen-induced arthritis, and obviously inhibit serious morbid degree and morbidity. The berberine can downwards regulate tumor necrosis factor alpha, interleukin 17 and interferon gamma in splenocyte supernate, and inhibit the secretion of proinflammatory cytokines TNF-alpha, IFN-gamma and IL-17 so as to prepare the medicament for preventing and treating the rheumatoid arthritis with great clinical application value. The medicament is a medicinal composition prepared from the berberine serving as an active ingredient and conventional pharmaceutical adjuvant, and comprises tablets, dispersible tablets, buccal tablets, orally disintegrating tablet, sustained release tablets, capsules, soft capsules, pills, granules, injection, powder injection or aerosol.

The invention relates to a fluorescent quantitative PCR method for detecting interleukin 17 in pig intestinal tissue. The method comprises the following steps: designing a specific fluorescent quantitative PCR primer, establishing a fluorescent quantitative PCR reaction system and a reaction process, preparing plasmids as standard plasmids for drawing standard curve, finally detecting the gene expression quantity according to relative quantification triangle triangle CT method after target genes and reference genes GAPDH of samples to be tested are amplified simultaneously, wherein the plasmids contain target fragment IL-17. Due to the adoption of the characteristics of high sensitivity, strong specificity, no pollution, real time, accuracy and high speed of the fluorescent quantitative PCR, the invention provides a practical method for detecting IL-17 expression level of pig intestinal part, so that evaluation of immune state or disease process of the animal intestinal part is assisted.

The invention discloses dihydroartemisinin oxime-containing phenol derivatives as well as a synthesis method and application thereof, and belongs to the technical field of chemical medicines. The derivatives or racemates, stereoisomers, tautomers and pharmaceutically acceptable salts thereof have the following general formula shown in the specification. The invention also discloses the synthesis method of the derivatives, and the application of the derivatives in antituberculotic, antidiabetic, lipid-lowering and interleukin-17 inhibition drugs.

The invention provides a derivative of 1-O-caffeoylquinic acid shown in the formula II, 1-O-caffeoylquinic acid and of the derivative and application of 1-O-caffeoylquinic acid shown in the formula IIand salt thereof. 1-O-caffeoylquinic acid, the derivative of 1-O-caffeoylquinic acid showing in the formula II and salt thereof have the effect of inhibiting interleukin 17, particularly secretion ofinterleukin 17F, and can also prevent and treat tumors. An experiment result shows that when the concentration of 1-O-caffeoylquinic acid is 0.5 MUM / L, the inhibition rate of interleukin 17F is closeto 70%; when the dose of 1-O-caffeoylquinic acid is 20 mg / kg, 1-O-caffeoylquinic acid has a good inhibiting effect on melanoma and tumors like pancreatic cancer, colorectal cancer and lung cancer, the inhibition rates all exceed 50%, and the derivative of 1-O-caffeoylquinic acid also has a good inhibiting effect on melanoma and the tumors like pancreatic cancer, colorectal cancer and lung cancer,wherein the formula II is shown in the formula II.

The invention discloses a kit that is used for detecting the genetic predisposition of children asthma. The kit comprises particularity primer pairs and particularity fluorescent probe pairs that are used for simultaneously detecting six SNP loci on the four genes of dissociation agent-metalloproteinase (ADAMTS12) that has the encoding of thrombin-sensitive protein motif 12, E74-like factor 5 (ELF5), interleukin-17 (IL-17) and receptor-typed protein tyrosine phosphatase D (PTPRD) and a routine component that is used for fluorescent quantitative PCR detection, etc. The kit of the invention evaluates the genetic predisposition of children asthma by simultaneously detecting the mononucleotide polymorphism locus genotypes that are closely related with the genetic predisposition of children asthma.

Disclosed herein is a vaccine comprising an antigen and IL-17. Also disclosed herein is a method for increasing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.

The invention discloses primers and probe for detecting amount of gene expression of interleukin 17-5 of a pacific oyster by PCR. According to primer and probe nucleotide sequences, a forward primer is 5'-tccctggtccaccatcatg-3', a reverse primer is 5'-ggaacaccactgaggacttgg-3', and the probe is 5'-cgcgtcagctacc-3'. A fluorescent group added to the probe is 6-carboxyfluorescein. The accuracy and specificity of the primers and the probe are high, so the digital PCR technology is used for detecting the sequential variation of the interleukin 17-5 of the pacific oyster, and the result is used as anindex to evaluate the health status of the farmed pacific oyster. An established evaluation system has potential application value in early warning and prediction of diseases of farmed shellfishes, acontrol group or an internal control gene is not required, and the application limitation of a traditional fluorescence real-time quantitative PCR detection method is broken through.

The present disclosure relates to methods for treating new-onset plaque-type psoriasis patients and inhibiting the progression of structural damage in these patients, using Interleukin-17 (IL-17) antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating new-onset plaque-type psoriasis patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood / serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and / or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and / or fluticasone with 17-OPHC.

The invention discloses preparation and application of a porcine interleukin 17 and 22 co-expression antibiotic-replacing biological preparation. The invention provides a fusion protein. The fusion protein comprises porcine interleukin 17 and porcine interleukin 22. The protein is specifically a protein shown in a sequence 1 or a sequence 3. Nucleic acid molecules encoding the protein also belong to the protection range of the invention. Expression cassettes, recombinant vectors, transfected cells or recombinant microorganisms with the nucleic acid molecules all belong to the protection range of the invention. The invention also provides a culture product of the transfected cell or a fermentation product of the recombinant microorganism. The invention also protects the application of the biological material: preparation of a product for improving animal immunocompetence; improving the animal immunity; preparing a vaccine; resisting pathogenic microorganism infection; the biological material is the protein or the nucleic acid molecule or the expression cassette or the recombinant vector or the transfected cell or the recombinant microorganism or the culture product or the fermentation product.

According to the invention, experimental autoimmune neuritis is used as an experimental environment to research intervention effect of zidovudine on the immune system. It is found through experiments that zidovudine can increase expression quantity of nuclear transcription factor 2 and heme oxygenase 1 so as to induce differentiation of M1-type macrophage to M2-type macrophage and furthermore promote neighboring cell proliferation and tissue repairing by the utilization of cytokines released by the M2-type macrophage. In addition, it is found that oral administration of zidovudine can down-regulate messenger RNA level of pro-inflammatory cytokines gamma-interferon, tumor necrosis factor alpha, interleukin 6 and interleukin 17 and up-regulate messenger RNA level of anti-inflammatory cytokines interleukin 4 and 10 so as to improve inflammatory injury in an EAN model. Based on the above positive discovery, the new application of zidovudine for preparation of a medicine for treating autoimmune neuritis is determined. The invention is of positive clinical significance.

The invention provides an application of omeprazole in preparing a medicine for treating autoimmune disease. Based upon experiments, the omeprazole, through oral administration, can take a concrete effect on relieving the autoimmune disease, in particular inflammatory injury caused by the autoimmune disease. Further experiments show that the omeprazole can down-regulate mRNA levels of four proinflammatory cytokines, namely [gamma] interferon in a spleen with EAN (experimental allergic neuritis), tumor necrosis factor [alpha], interleukin 6 and interleukin 17, and meanwhile, the omeprazole can up-regulate mRNA levels of two proinflammatory cytokines, namely interleukin 4 and interleukin 10. Moreover, cytokine expression profile of ELISA detection also shows a similar trend in a spleen mononuclear cell culture supernatant. On the basis of the pharmacological properties, the omeprazole, which can take the effect on treating the autoimmune disease, is applicable to preparation of the medicine for treating the autoimmune disease.

The invention discloses application of interleukin 17 in resisting of infection of influenza virus. The invention provides application of IL-17 protein in preparation of products for inhibiting influenza virus from infecting cells, application of IL-17 protein in preparation of influenza virus resisting products, and application of IL-17 protein in application of products for inhibiting influenza virus from growing in cells. The experiment shows that interleukin 17 can be used for resisting influenza virus from infecting the cells and has a large value on preventing and control of influenza virus.

The invention discloses application of lactobacillus acidipiscis for preparing a medicine capable of preventing and / or treating autoimmune diseases. The invention firstly provides the lactobacillus acidipiscis, Treg cell differentiation is obviously accelerated, TH1 cell or TH17 cell differentiation is inhibited, the generation of cell factors IFN (interferon)-[gamma] or IL-17 (interleukin 17) isinhibited, the generation of cell factors IL-10 or IL-13 is accelerated, and the inflammatory reaction of the autoimmune diseases is obviously reduced. The invention also provides a medicine for treating the autoimmune diseases. The medicine comprises an effective dosage of lactobacillus acidipiscis. After a patient takes the medicine, an obvious effect for treating the autoimmune diseases is achieved, no toxic and side effects are generated, and in addition, the lactobacillus acidipiscis can be conveniently obtained. Therefore, the lactobacillus acidipiscis has a wide application prospect inthe medicine capable of treating the autoimmune diseases.

The invention discloses application of a compound and an analogue thereof as an ROR gamma regulator, and relates to the technical field of medicines. The compound is panaxadiol and analogues thereof, and the analogues comprise panaxatriol, protopanaxadiol, protopanaxatriol and a newly synthesized analogue. The newly synthesized analogue is a novel panoxadiol analogue which is designed and synthesized on the basis of a combination mode of panoxadiol and an ROR gamma three-dimensional crystal structure. The compound can be applied to preparation of drugs for treating or preventing diseases related to ROR gamma regulation. The compound can be applied to preparation of drugs for treating or preventing interleukin 17 regulation related diseases. The invention also discloses application of the compound or the pharmaceutically acceptable salt thereof in preparation of a pharmaceutical preparation for preventing or treating and regulating ROR gamma related diseases. The invention also relates to application of the compound in preparation of pharmaceutical compositions used in combination with other pharmaceutical preparations for preventing or treating and regulating ROR gamma-related diseases.

The present disclosure relates to methods for treating non-radiographic axial spondyloarthritis (nr-axSpA) patients and inhibiting the progression of structural damage in these patients, using Interleukin-17 (IL-17) antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating nr-axSpA patients and inhibiting the progression of structural damage in these patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

The invention discloses an enzyme-linked immunoassay method for quantitatively detecting the content of an anti-human interleukin 17 monoclonal antibody in serum. The invention relates to an antibody,a heavy chain and a light chain of the antibody, a corresponding variable domain and a corresponding complementary decision domain, and an enzyme-linked immunoassay method established using the antibody as a secondary antibody in BA-ELISA analysis.

This invention discloses an acceptor of inferleukin 17 and its code and their application, the objective is to provide an acceptor of inferleukin 17 and its code gene and their application of preparing mark substance for diagnose tumour and treatment medicine for RAS / MAPK signal access related diseases. The albumen is a protein with following one of the sequence of amino-acid residue radical: 1) SEQ ID No: 2 in sequence table; 2) amino-acid residue radical sequence in SEQ ID No: 2 in the sequence table are replaced by one to ten of amino-acid residue radical, lose or added and through activating RAS / MAPK signal access and with promoting karyokinesis action protein. inferleukin 17 acceptorof this invention will play a important roll in diagnose tumor, since its code gene mIL-17RE interferes the code gene of RNA, it can be used as active component to prepare medicine, for treatment diseases related to RAS / MAPK signal access, such as prostate tumour, leukaemia and thyroid gland tumour and other diseases. The invention has more practical meaning and wide application prospect in medical science and biological pharmacy field.

The invention provides the application of berberine in the preparation of medicines for preventing and treating rheumatoid arthritis. The invention adopts the berberine to carry out the animal efficacy test, and the result shows that the berberine can inhibit the clinical onset of collagen-induced arthritis, and obviously inhibit the severity and incidence rate of the onset. And can down-regulate tumor necrosis factor α, interleukin 17, interferon γ in spleen cell supernatant, inhibit the secretion of pro-inflammatory cytokines TNF-α, IFN-γ and IL-17, so as to prepare drugs for preventing and treating rheumatoid arthritis, It has great clinical application value. The medicine is a pharmaceutical composition made of berberine as an active ingredient and conventional pharmaceutical excipients, including tablets, dispersible tablets, buccal tablets, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, Granules, injections, powder injections or aerosols.